Two patients who were given an experimental Ebola treatment in the DR Congo's current outbreak have recovered.  Health officials will now monitor their progress to determine what role the treatment played in their recovery.

The two were in a group of ten people receiving the mAb114 treatment, which was developed from antibodies of a man who survived an Ebola outbreak in 1995.  This fellow had one heck of a strong immune system; researchers have used his antibodies to cure Ebola-stricken monkeys even five weeks after infection.

That treatment is one of several that DR Congo health officials have approved to battle the country's second outbreak in 2018.  The others are ZMapp, Remdesivir, Favipiravir and Regn3450 - 3471 - 3479.  The head of the World Health Organization (WHO) applauded the decision, calling it "a global first, and a ray of hope for people with the disease."

Health officials are confirming 79 infections, including 42 deaths and 14 people who have recovered.  They also suspect another 28 probable infections, but haven't been able to confirm them through laboratory testing.